User:Emanresuofdnow/sandbox

Guangzhou Wondfo Biotech Co., Ltd. (simplified Chinese: 广州万孚生物技术股份有限公司; pinyin: Guǎng Zhōu Wàn Fú Shēng Wù Jì Shù Gǔ Fèn Yǒu Xiàn Gōng Sī) is a biological enterprise providing rapid medical test and chronic disease management solutions in the biomedical in vitro diagnostic (IVD) industry. Headquartered in Guangzhou, China, Wondfo was established in 1992.

History
Wondfo was co-founded by Wang Jihua and Li Wenmei in 1992 and went public in 2015 on the Shenzhen Stock Exchange. It grew by providing rapid tests of pregnancy and infectious diseases and developed immunofluorescence analyzers, Finecare™ FIA Meters. Its subsidiaries include Wondfo USA subsidiary (founded in 2009), Guangzhou Accurate and Correct Test Co., Ltd. (founded in 2012), Wondko (founded in 2018). In late 2021, Wondfo acquired Shenzhen Tisenc Medical Equipment Co., Ltd. for 100% of the equity. In April 2022, China's National Medical Products Administration approved a batch of COVID-19 antigen self-testing kits, including Wondfo's 2019-nCoV antigen test. According to Newsgd, a local press, the daily production capacity of COVID-19 antigen test kits can reach up to more than tens of millions to meet domestic and oversea demands.